retatrutide peptide vs semaglutide Tirzepatide vs | Metabolic Comparison Retatrutide vs Semaglutide: Which Wins

There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape

Similarly, the occurrence of adverse events did not differ between the study groups

GLP-1 (glucagon-like peptide-1) is a specific peptide consisting of 30-31 amino acids

On a broader societal level, the use of GLP-1 medications for weight loss may be reinforcing the negative stigmas around fatness and being overweight that often contribute to the development of eating disorders